Biogen Pharma

Why is Biogen Pharmachem Industries Ltd falling/rising?

As of 09-Aug, Biogen Pharmachem Industries Ltd's stock price is at 0.28, reflecting a significant decline of -52.54% year-to-date and -64.56% over the past year, underperforming the benchmark Sensex. The stock is also trading below its moving averages and experiencing decreased investor interest, nearing its 52-week low.

As of 09-Aug, Biogen Pharmachem Industries Ltd's stock price is falling, currently at 0.28, which reflects a change of -0.01 or -3.45%. This decline is evident in the stock's performance over various periods, with a significant drop of -52.54% year-to-date and -64.56% over the past year. Comparatively, the benchmark Sensex has shown a much smaller decline of -7.89% year-to-date and -2.63% over the past year, indicating that Biogen is underperforming relative to the market.<BR><BR>Today's trading performance further highlights the stock's struggles, as it is underperforming its sector by -1.44%. Additionally, the stock is trading lower than its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests a consistent downward trend in its price.<BR><BR>Investor participation has also decreased, with delivery volume falling by -32.51% compared to the 5-day average, indicating reduced interest from investors. The stock is close to its 52-week low, being only 3.57% away from a low of Rs 0.27. Overall, these factors contribute to the ongoing decline in Biogen Pharmachem Industries Ltd's stock price.

Which are the latest news on Biogen Pharma?

Are Biogen Pharmachem Industries Ltd latest results good or bad?

Biogen Pharmachem Industries Ltd's latest results are concerning, showing a net profit of ₹0.22 crores but generating zero revenue, indicating reliance on non-core income. With a low return on equity of 2.22% and a 63.75% decline in stock value over the past year, the company's fundamentals suggest significant struggles ahead.

Biogen Pharmachem Industries Ltd's latest results present a concerning picture. While the company reported a net profit of ₹0.22 crores for Q1 FY27, this profit is overshadowed by the fact that it has generated zero revenue across all recent quarters. The profit appears to be driven entirely by fluctuations in other income rather than from core business operations, raising serious questions about the sustainability of its earnings.<BR><BR>Moreover, the company's return on equity (ROE) stands at a meager 2.22%, which is significantly below acceptable standards, indicating poor capital efficiency. The stock has also experienced a dramatic decline of 63.75% over the past year, underperforming the broader market significantly.<BR><BR>In terms of operational performance, the company has shown erratic profitability, with a history of alternating between profits and losses. The absence of institutional investor confidence, with zero holdings from foreign or domestic institutions, further exacerbates concerns about its viability.<BR><BR>Overall, while the latest quarter shows a profit, the underlying fundamentals suggest that the company is struggling significantly, making the results more indicative of a value trap rather than a positive turnaround.

Should I buy, sell or hold Biogen Pharmachem Industries Ltd?

When is the next results date for Biogen Pharmachem Industries Ltd?

The next results date for Biogen Pharmachem Industries Ltd is August 5, 2026.

The next results date for Biogen Pharmachem Industries Ltd is scheduled for August 5, 2026.

How big is Biogen Pharma?

As of 10th June, Biogen Pharmachem Industries Ltd has a market capitalization of 38.00 Cr and reported net sales of 0.00 Cr with a net profit of 0.95 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Biogen Pharmachem Industries Ltd has a market capitalization of 38.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 0.00 Cr, while the sum of Net Profit for the same period is 0.95 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 91.93 Cr and Total Assets totaling 92.02 Cr.

Who are in the management team of Biogen Pharma?

The management team of Biogen Pharma includes Niraj Vaghela (Whole Time Director & CFO), Chandrakant Govingbhai Parmar, Manjulaben Parmar (both Independent Directors), Khushboo Khandelwal (Company Secretary & Compliance Officer), and directors Harshadkumar Rathod, Narendrakumar Vaniya, and Komalben Chauhan.

The management team of Biogen Pharma includes the following individuals:<BR><BR>1. **Niraj Vaghela** - Whole Time Director & CFO<BR>2. **Chandrakant Govingbhai Parmar** - Independent Director<BR>3. **Manjulaben Parmar** - Independent Director<BR>4. **Khushboo Khandelwal** - Company Secretary & Compliance Officer<BR>5. **Harshadkumar Rathod** - Director<BR>6. **Narendrakumar Vaniya** - Director<BR>7. **Komalben Chauhan** - Director<BR><BR>If you have any more questions or need further details, feel free to ask!

Who are the peers of the Biogen Pharma?

Biogen Pharma's peers include Ajcon Global, Prism Medico, Kiduja India, Anupam Finserv, Madhusudan Sec., Glance Finance, HB Stockholdings, Nagreeka Cap., and JMJ Fintech. Key insights show varying management risks, growth ratings, and capital structures, with Prism Medico leading in 1-year returns at 87.28%, while Biogen Pharma's return is -64.95%.

Peers: The peers of Biogen Pharma are Ajcon Global, Prism Medico, Kiduja India, Anupam Finserv, Madhusudan Sec., Glance Finance, HB Stockholdings, Nagreeka Cap., JMJ Fintech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ajcon Global, Anupam Finserv, Madhusudan Sec., Glance Finance, HB Stockholdings, and JMJ Fintech, while Below Average management risk is found at Prism Medico, Kiduja India, and the rest. Growth ratings show Excellent growth at Madhusudan Sec., JMJ Fintech, and the rest, while Below Average growth is noted at Ajcon Global, Prism Medico, Anupam Finserv, and the rest. Capital Structure is Excellent for Ajcon Global, Anupam Finserv, Madhusudan Sec., Glance Finance, HB Stockholdings, and JMJ Fintech, while Good is noted for Biogen Pharma, and Below Average is found at Prism Medico, Nagreeka Cap., and the rest.<BR><BR>Return Snapshot: Prism Medico has the highest 1-year return at 87.28%, while JMJ Fintech has the lowest at -65.44%, with Biogen Pharma's 1-year return at -64.95% being slightly better than JMJ Fintech's. Additionally, peers such as Ajcon Global, Anupam Finserv, Madhusudan Sec., Glance Finance, HB Stockholdings, JMJ Fintech, and Biogen Pharma all have negative six-month returns.

What does Biogen Pharma do?

Biogen Pharmachem Industries Ltd is a micro-cap NBFC involved in trading shares, securities, and commodities. The company, formerly known as Wellworth Overseas Limited, reported a net profit of 0 Cr for the quarter ending March 2026 and has a market cap of INR 38 Cr.

Overview:<BR>Biogen Pharmachem Industries Ltd is engaged in trading shares and securities, commodities, including agro-based and precious metals, and operates within the Non Banking Financial Company (NBFC) industry in the micro-cap market.<BR><BR>History:<BR>The company was incorporated in July 1995 as Wellworth Overseas Limited, later changing its name to Sun Techno Overseas Limited in August 2011, and finally to Biogen Pharmachem Industries Limited on March 24, 2021. The most recent quarterly results reported net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 38 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 39.00<BR>Industry P/E: 21<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.00<BR>Return on Equity: 0.96%<BR>Price-to-Book: 0.39<BR><BR>Contact Details:<BR>Address: Shop No 8 First Floor, Makers 1 Building Jawahar Road Rajkot Gujarat : 360001<BR>Phone: 91-79-27498832<BR>Email: suntechnooverseas@gmail.com<BR>Website: http://www.biogenpharma.shop

What is the bonus history of Biogen Pharma?

Biogen Pharma recently announced a bonus issue at a ratio of 1:6, with an ex-date and record date set for May 15, 2026. Shareholders will receive one additional share for every six shares held.

Biogen Pharma has a recent bonus issue announced at a ratio of 1:6, with the ex-date set for May 15, 2026. This means that for every six shares held, shareholders will receive one additional share as a bonus. The record date for this bonus issue is also May 15, 2026. If you have any more questions about Biogen or its financial activities, feel free to ask!

How has been the historical performance of Biogen Pharma?

Biogen Pharma has experienced significant financial fluctuations, with net sales dropping to zero by March 2025 after a modest increase in previous years, while total expenditures rose sharply and profitability turned negative. Despite these challenges, shareholder funds increased, and cash flow from financing activities remained positive.

Answer:<BR>The historical performance of Biogen Pharma shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Biogen Pharma's net sales have remained at zero from March 2023 to March 2025, following a modest increase to 2.47 crore in March 2022 from 1.62 crore in March 2021. Other operating income peaked at 2.38 crore in March 2024 but dropped to zero in March 2025. Total operating income followed a similar trend, reaching 2.16 crore in March 2022 before declining to zero by March 2025. The company faced a total expenditure of 1.13 crore in March 2025, a significant increase from 0.45 crore in March 2024, while operating profit (PBDIT) turned negative at -0.29 crore in March 2025, contrasting with a profit of 1.93 crore in March 2024. Profit before tax also fell to -0.29 crore in March 2025 from 1.93 crore in the previous year. The company's reserves have been negative, reaching -9.03 crore in March 2025, and shareholder's funds increased to 91.93 crore in March 2025 from 56.52 crore in March 2024. Cash flow from operating activities was negative at -1.00 crore in March 2025, while cash flow from financing activities showed a positive inflow of 35.00 crore. Overall, Biogen Pharma's financial performance has been marked by instability, with recent years showing a decline in sales and profitability, despite an increase in cash reserves.

Who are the top shareholders of the Biogen Pharma?

The top shareholders of Biogen Pharma are individual investors, holding 47.04% of shares, with Rama Shiva Lease Finance Private Limited as the largest public shareholder at 9.31%. There are no institutional shareholders or pledged promoter holdings.

The top shareholders of Biogen Pharma include individual investors, who collectively hold 47.04% of the shares. The highest public shareholder is Rama Shiva Lease Finance Private Limited, which holds 9.31%. There are no institutional shareholders or mutual funds currently holding shares in the company, and there are no pledged promoter holdings.

Is Biogen Pharma overvalued or undervalued?

As of May 26, 2025, Biogen Pharma is considered very expensive and overvalued due to a negative PE ratio of -61.34, an EV to EBIT ratio of 55.88, and a low ROE of -0.51%, despite a 357.14% stock increase over five years, which underperformed against the Sensex's 7.62% return in the last year.

As of 26 May 2025, the valuation grade for Biogen Pharma has moved from risky to very expensive. The company is currently overvalued, as indicated by its PE ratio of -61.34, an EV to EBIT ratio of 55.88, and a Price to Book Value of 1.09. These ratios highlight significant concerns regarding profitability and valuation relative to its assets.<BR><BR>In comparison to its peers, Biogen Pharma's valuation stands out unfavorably; for instance, MMTC has a PE ratio of 119.39, while Elitecon International shows a PE of 131.08, both indicating a more favorable valuation in the market. Additionally, Biogen's return on equity (ROE) is at -0.51%, further emphasizing its struggles compared to competitors. While Biogen's stock has seen a notable increase of 357.14% over the past five years, it has underperformed against the Sensex in the last year, which returned 7.62%. This context reinforces the conclusion that Biogen Pharma is currently overvalued.

What is the technical trend for Biogen Pharma?

As of May 19, 2025, Biogen Pharma's trend is mildly bearish, indicated by daily moving averages and monthly MACD, while weekly indicators show mixed signals, leading to a moderate bearish outlook.

As of 19 May 2025, the technical trend for Biogen Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the monthly MACD showing a mildly bearish signal. Weekly indicators present a mixed picture with the MACD and KST both mildly bullish, while Bollinger Bands remain bearish. The lack of clear signals from the RSI further supports the neutral to mildly bearish outlook. Overall, the strength of the bearish trend is moderate, influenced by the recent price action and the broader market context.

Has Biogen Pharma declared dividend?

No Dividend History Available